文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability.

作者信息

Enkhmaa Byambaa, Kim Kyoungmi, Zhang Wei, Prakash Nishant, Truax Kevin, Anuurad Erdembileg, Berglund Lars

机构信息

Departments of Internal Medicine, University of California, Davis, CA, USA.

Public Health Sciences, University of California, Davis, CA, USA.

出版信息

J Endocr Soc. 2020 Jun 11;4(7):bvaa073. doi: 10.1210/jendso/bvaa073. eCollection 2020 Jul 1.


DOI:10.1210/jendso/bvaa073
PMID:32685870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7358566/
Abstract

CONTEXT: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces lipoprotein(a) [Lp(a)] levels, but the association of PCSK9 with Lp(a) level and its major determinant, apolipoprotein(a) [apo(a)] size, is not fully understood. OBJECTIVE: To assess the relationship between PCSK9, Lp(a) level, apo(a) size, age, and ethnicity/race. DESIGN: Cross-sectional. SETTING: General population. PARTICIPANTS: Healthy African Americans and Caucasians (n = 267); age range: 6 to 74 years. INTERVENTIONS: None. MAIN OUTCOME MEASURES: PCSK9 levels, apo(a) isoform and allele sizes, and isoform-specific Lp(a) levels. RESULTS: Plasma PCSK9 levels were significantly higher in African Americans vs Caucasians, in females vs males, and in adults vs children. PCSK9 levels were not associated with total plasma Lp(a) levels either in all participants or in ethnicity-specific analyses. However, PCSK9 levels were significantly positively associated with isoform-specific Lp(a) levels carried by the larger apo(a) size in all participants ( = 0.139,  = 0.0361). In ethnicity/race analyses, a significant association was seen for African Americans ( = 0.268,  = 0.0199), but not for Caucasians. In contrast, there were no significant associations of PCSK9 with isoform-specific Lp(a) levels for the smaller apo(a) sizes in all participants nor in ethnic-specific analyses. Furthermore, heritability (h) analyses revealed a significant heritability for PCSK9 level in both ethnic groups, with a higher estimate in Caucasians than in African Americans (47% vs 22%, respectively). CONCLUSIONS: Among African Americans, but not Caucasians, PCSK9 levels were associated with isoform-specific Lp(a) levels carried on larger, but not smaller, apo(a) sizes. The findings illustrate a diverging relationship of PCSK9 with isoform-specific Lp(a) levels across ethnicity.

摘要

相似文献

[1]
PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability.

J Endocr Soc. 2020-6-11

[2]
Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians.

J Lipid Res. 2002-2

[3]
Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families.

J Lipid Res. 2019-7-18

[4]
Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population.

Atherosclerosis. 2010-4-20

[5]
Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Atherosclerosis. 2014-7

[6]
Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Transl Res. 2011-2-5

[7]
Lp(a)-Associated Oxidized Phospholipids in Healthy Black and White Participants in Relation to apo(a) Size, Age, and Family Structure.

J Am Heart Assoc. 2021-9-7

[8]
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.

Atherosclerosis. 2018-10

[9]
High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans.

J Clin Endocrinol Metab. 2008-4

[10]
The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.

J Lipid Res. 2017-8-10

引用本文的文献

[1]
Epigenetic editing in cardiovascular medicine: moving beyond the hype.

Nat Rev Cardiol. 2025-6

[2]
The evolving landscape of PCSK9 inhibition in cancer.

Eur J Pharmacol. 2023-6-15

[3]
Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis.

Front Cardiovasc Med. 2021-11-23

[4]
Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.

Hum Mol Genet. 2022-3-21

[5]
Bridging the Racial Disparity Gap in Lipid-Lowering Therapy.

J Am Heart Assoc. 2021-1-5

本文引用的文献

[1]
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials.

J Clin Lipidol. 2019-6-27

[2]
Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype.

Atherosclerosis. 2019-7-3

[3]
Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families.

J Lipid Res. 2019-7-18

[4]
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

J Clin Lipidol. 2019-5-17

[5]
PCSK9 and Lp(a) levels of children born after assisted reproduction technologies.

J Assist Reprod Genet. 2019-5-11

[6]
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.

J Am Coll Cardiol. 2018-11-11

[7]
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

N Engl J Med. 2018-11-7

[8]
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.

Atherosclerosis. 2018-10

[9]
The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.

J Lipid Res. 2017-8-10

[10]
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

N Engl J Med. 2017-3-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索